Targeting tumor-stroma crosstalk: The example of the NT157 inhibitor

Oncogene

Volumn 35, Issue 20, 2016, Pages 2562-2564

  Rampias, T ^a   Favicchio, R ^b   Stebbing, J ^b   Giamas, G ^a,b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NT 157; SOMATOMEDIN RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; NT157 COMPOUND; PYROGALLOL; SULFONAMIDE;

CANCER CELL; CANCER GROWTH; CELL SURVIVAL; COLON CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; STROMA; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PYROGALLOL; STROMAL CELLS; SULFONAMIDES; TUMOR MICROENVIRONMENT;

EID: 84970973792     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.392     Document Type: Review

References (18)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett 2015; e-pub ahead of print 10 August 2015; doi:10.1016/j.canlet.2015.07.044.
3. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54-59.
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
5. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer cell 2015; 27: 462-472.
6. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
8. Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A et al. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene 2016; 35: 2675-2680.
9. Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 2015; epub ahead of print 14 September 2015; doi:10.1038/onc.2015.326.
10. Stebbing J, Zhang H, Xu Y, Grothey A, Ajuh P, Angelopoulos N et al. Reprogramming of the tyrosine kinase-regulated proteome in breast cancer by combined use of RNAi and SILAC quantitative proteomics. Mol Cell Proteomics 2015; 14: 2479-2492.
11. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169.
12. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014; 5: 3472.
13. Castano Z, Marsh T, Tadipatri R, Kuznetsov HS, Al-Shahrour F, Paktinat M et al. Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov 2013; 3: 922-935.
14. Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi X, McClelland M et al. Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-beta and IGF signaling. BioMed Res Int 2014; 2014: 502093.
15. Kawada M, Inoue H, Masuda T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006; 66: 4419-4425.
16. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
17. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
18. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9721-9730.